A subgroup analysis of patients with core binding factor (CBF) AML further highlighted this trend: CRi patients had a higher relapse risk compared with those in CR/CRh (45.6% vs. 22%). The gene discussed is CEBPZ; the disease is acute myeloid leukemia.